StockNews.AI
NAGE
StockNews.AI
152 days

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

1. NAGE expands its NAD+ precursor IP with a new U.S. patent. 2. The patent covers novel NR salt forms and derivatives.

2m saved
Insight
Article

FAQ

Why Bullish?

The new patent strengthens NAGE's market position, following historical trends seen with similar tech advancements. Companies with expanded IP portfolios often experience positive stock performance due to potential exclusivity in a growing market.

How important is it?

The announcement of a new patent is vital for NAGE's growth trajectory and investor confidence. Proprietary technologies grant strategic advantages in high-demand sectors like healthy aging.

Why Long Term?

The patent grants NAGE a competitive edge, promising long-term benefits as the market for anti-aging supplements grows. Historical instances show patents can maintain valuation spikes over extended periods, particularly in biotech.

Related Companies

CHRMNVSCZR
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #IP--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent 12,252,506, which covers the composition of matter for nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate, and other NR derivatives. This is p.

Related News